← All trials
NCT06375811
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2024
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Apr 19, 2024
- Last posted
- Apr 23, 2024
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- Duke UniversityCollaborator
- University of Colorado, DenverOfficial
- Duke UniversityOfficial
- University of Colorado, DenverCollaborator
- University of North Carolina at Chapel HillCollaborator
- Yale UniversityOfficial
- Northwestern UniversityOfficial
- Northwestern UniversityCollaborator
- Johns Hopkins UniversityOfficial
- Johns Hopkins UniversityCollaborator
- Yale UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.